CA3076714C - Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof - Google Patents

Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof Download PDF

Info

Publication number
CA3076714C
CA3076714C CA3076714A CA3076714A CA3076714C CA 3076714 C CA3076714 C CA 3076714C CA 3076714 A CA3076714 A CA 3076714A CA 3076714 A CA3076714 A CA 3076714A CA 3076714 C CA3076714 C CA 3076714C
Authority
CA
Canada
Prior art keywords
flask
added
acid
mmaf
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3076714A
Other languages
French (fr)
Other versions
CA3076714A1 (en
Inventor
Lele LI
Changjiang Huang
Youxiang Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabplex International Co Ltd
Original Assignee
Mabplex International Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabplex International Co Ltd filed Critical Mabplex International Co Ltd
Priority claimed from PCT/CN2019/118446 external-priority patent/WO2021056754A1/en
Publication of CA3076714A1 publication Critical patent/CA3076714A1/en
Application granted granted Critical
Publication of CA3076714C publication Critical patent/CA3076714C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided is a method for producing an antibody-drug conjugate intermediate by addition of acid. An acid additive is used to convert the monomethyl auristatin derivative into a salt thereof to participate in the reaction. The addition of the acid additive can significantly improve the yield of the final product. In addition, the low price of the acid additive greatly reduces the production cost of the final ADC product. Moreover, the method of the present invention adopts a one-step preparation process, in addition to a higher yield of the final product, not only reducing the cost of the consumables, labor, equipment, site, raw materials and the like in the production, but also greatly reducing the production of the waste liquid, and thus reducing production costs and improving production efficiency, and making the method suitable for industrial large-scale production.

Description

METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
INTERMEDIATE BY ADDITION OF ACID AND USE THEREOF
Field of the invention [0001] The present invention relates to the field of antibody-drug conjugates, in particular to a method for producing an antibody-drug conjugate intermediate and its use in the production of antibody-drug conjugates.
Background of the invention
[0002] Antibody-Drug Conjugate (ADC), as a new type of biological missile, achieves an advantageous combination of the targeting effect of monoclonal antibodies and the cytotoxic effect of small molecule drugs, and has now become one of the fastest developing fields in tumor targeted therapy. The three components (antibodies, cytotoxins and linkers) of ADC together constitute a targeted drug delivery system, in which the antibodies provide the targeting effect, the linkers ensure the stability of the ADC in the blood transport process, and the toxins exert killing effect on cancer cells after reaching the target.
[0003] Currently, auristatins or maytansinoids are the two most widely used mitotic inhibitors in ADC development. They can bind to tubulin near the vinblastine binding site, causing cell cycle arrest at G2/M phase and subsequent cell apoptosis.
This cell killing mechanism is very effective in rapidly proliferating cells, but non-dividing and static cells may be less sensitive to drug effects, and thus have drug resistance.
Because tumor cells divide faster than most normal cells, anti-mitotic drugs are particularly effective for cancer cells. Due to this inherent selectivity, tubulin inhibitors with high efficacy, such as maytansin and auristatin, have been successfully used as clinically approved ADC drugs (brentuximabvedotin and trastuzumabemtansine, etc.).
[0004] Dolastatin is a class of linear polypeptide compounds with high cytotoxicity found in Dolabella scapula in the Indian Ocean, and such cytotoxic drugs can significantly inhibit formation and polymerization of tubulin. However, Dolastatin 10, when used alone, has problems such as large toxic side effects, poor pharmacokinetic properties, and narrow therapeutic window, limiting its development. Miyazaki et al.
found that monomethyl auristatin D (MMAD) with a secondary amine at the N-terminus has comparable toxicity to Dolastatin10, so such N-monomethyl substituted Dolastatin derivative is termed auristatin. Such compound can be effectively connected to the linker, and based on this, a new generation of high-efficiency ADC has been generated. At present, the warhead molecules commonly used in ADC research and development are auristatin compounds MMAE
and MMAF (Hu Xinyue, Li Yanping, Li Zhuorong. Progress in the research of warhead molecules for antibody-drug conjugates [J]. China Medical Biotechnology, 2017 (6): 549- 555.).
[0005] MMAF (Monomethyl auristatin F) is a derivative of dolastatin10 (D10), which can inhibit cell mitosis and has strong antitumor activity. At present, MMAF is used as cytotoxic molecule in various ADC products in clinical stage, and is the most used monomethyl auristatin derivative in ADC. However, these small molecule drugs are expensive.
[0006] The market price of MMAF is close to 5,000 yuan per 10 mg, while the market price of Mc-MMAF intermediate used for coupling to antibodies is close to 6000 yuan per .lmg. The price from MMAF to Mc-MMAF intermediate has increased more than ten times (the prices of MMAF and Mc-MMAF can be found at the following URL:
https://www.medchemexpress.cn/mmaf-hydrochloride.html?src=360-product, https://www.medchemexpress.cn/McMMAF.html). The high price of ADC
intermediates is a main reason for the high cost of related ADC production.
[0007] An important reason for the increasing price of related ADC
intermediates (linker-drug covalent conjugates) relative to the corresponding cytotoxic molecules is the low yield of the antibody-drug conjugate intermediates during the preparation process. Therefore, increasing the yield of related ADC intermediates can effectively control the cost of ADC drugs on a large scale.
[0008] The structure of Mc-MMAF is shown below:
NH
XI, NH Ni.'"CytC-Mr The structure of Mc-MMAE is shown below:

OH

The Mc-MMAD structure is shown below:

J.LNiCN3yr NH

I N NH
[0009] Chinese Patent Publication No. CN1938046A discloses two methods for preparing Mc-MMAF (Pages 206-207 of the specification and pages 207-208 of the specification, respectively), one of which is the synthesis of Mc-MMAF using tert-butyl ester, and the other is the synthesis of Mc-MMAF using dimethoxybenzyl esters. The reaction scheme of the two methods are as follows:
[0010] (1) Synthesis of Mc-MMAF using tert-butyl ester MIX,11111 0):1"-4, 'r.j'rli.'c(?1 004, 0 0 1011VIII-Ni000-01111-P101.003U, 1001 me4i.v.14.011Øp.p0.060 g.
MC-MAIAF
[NM (2) Synthesis of Mc-MMAF using dimethoxybenzyl ester HNIX1--0 004. 0 MOV014/4011.00p-P00-00148 e ,11,4 0 11:,,LJILTP...611...)4 MCANNal-Val4)1143apPliwOOM8 0 00s. 0 0 MC-MMAF
[0012] Both schemes use two-step synthesis processes. The synthesis of Mc-MMAF

using tert-butyl ester is performed by the initial synthesis of Mc-MMAF-OtBu (that is, Mc-MeVal-Val-Dil-Dap-Phe-OtBu), and following by deesterification with trifluoroacetic acid to obtain Mc-MMAF (total yield below 60%). The synthesis of Mc-MMAF using dimethoxybenzyl ester is performed by the initial synthesis of Mc-MMAF-ODMB (that is, Mc-MeVal-Val-Dil-Dap-Phe-ODMB), and following by deesterification with trifluoroacetic acid to obtain Mc-MMAF. The disadvantages of the two-step synthesis processes are that, the yield in the first step is 57%, the yield in the second step is 73%, and the total yield is only 42%; and MMAF-ODMB is not easy to be obtained.
[0013] Chinese Patent No. CN109824759A also discloses a method for producing Mc-MMAF (line [0009] on page 2 of the description) by directly reacting Mc with MMAF. Its reaction scheme is as follows:
NiLOH
NH-CO ________________________ mc MMAF MC-MMAF
[0014] The N-terminal valine of MMAF in this scheme has a methyl group on the N, which has a large steric hindrance, causing the reaction rate of attaching maleimido-hexanoic acid (Mc-hex-Acid) to MMAF slower. This scheme is used for the synthesis of MC-MMAF less than 1 g, and has a yield less than 50%, and high pressure reverse phase preparation is used to remove heterogeneous impurities.
5 Summary of the invention [0015] The present invention provides a method for producing an antibody-drug conjugate intermediate by addition of acid. The technical solutions of the present invention are as follows.
[0016] A method for producing an antibody-drug conjugate intermediate by addition of acid, wherein the reaction scheme of the method is as follows:
1. Ccnciensrig agent 2. Organic base 3. Solvent A
+ _________________________________________________________________ ) L' -monornathyl auristatin deriyatve Monomathyl auristatin derivative 4, Acid b. Solvent Li wherein L is a linking group containing an acyl;
L' is the residue of the linking group covalently attached to the monomethyl auristatin derivative;
solvent A and solvent B are polar or non-polar solvents; and the method comprises the following steps:
1) dissolving the linking group L, the condensing agent, and the organic base in the solvent A to obtain solution 1;
2) dissolving the monomethyl auristatin derivative and the acid in the solvent B
to obtain solution 2; and 3) adding the solution 1 into the solution 2 to obtain the L' -monomethyl auristatin derivative via the condensation reaction between L and the monomethyl auristatin derivative;
wherein the molar amount of the organic base used in step 1) is greater than the molar amount of all free carboxyl group in the reaction system of step 3).
[0017] Further, the the acid is one or more selected from trifluoroacetic acid and sulfonic acid.

[0018] Further, the monomethyl auristatin derivative includes MMAF, MMAE, and MMAD.
[0019] Further, the reaction scheme of the method is as follows:
L HN II 1),0 NI
0 '..'sTir I 0 1 I p o \ noX 0 0 NIMAF
1. Condensing agent 2. Organic base 0 rir,liciitTrNH
3. Solvent A
), NNH
4. Acid I 0 I /0 0 HC)' 0 5. Solvent B
L'AIMAF
or OH

WyN"
NI-01,1:ir0 0 Tjt.-L PIN

MMAE
1. Condensing agent OH
2. Organic base NTXIII(NH 0 NI I
3. Solvent A

4. Acid I I 0 5. Solvent B
Or L I il0 N
XIMAD
1. Condensing agent 2. Organic base 0 NH Ail 3. Solvent A

4. Acid I
I 0 / s 5. Solvent B
L.-MMAD

[0020] Further, the condensing agent is one or more selected from DCC, EDCI, DIC, HATU, HBTU, HBPIPU, HBPyU, HCTU, HDMA, TATU, TBTU, TCTU, TCFH, TDBTU, TFFH, B111-H, PyBOP, PyClOP, PyA0P, PyCIU, DEPBT and EEDQ;
preferably, the condensing agent is HATU.
[0021] Further, the organic base is one or more selected from N,N-diisopropylethylamine, triethylamine, pyridine, dimethylaminopyridine, triethylenedi amine, N-methylmorpholine, 1 , 8-diazabicyclo [5 .4.01 -7-undecene, N-methylimidazole, quinuclidine, and trimethylpyridine; preferably, the organic base is selected from N,N-diisopropylethylamine and triethylamine.
[0022] Further, the solvent A and the solvent B are each independently selected from DMF, DMA, NMP, methylene chloride, carbon tetrachloride, DMSO, chloroform, tetrahydrofuran, 1,4-dioxane, hexamethylphosphoryl triamide, N,N-dimethylpropyleneurea, ethylene glycol dimethyl ether and a mixture thereof, wherein the solvent A and the solvent B may be the same or different;
preferably, the solvent A and the solvent B are selected from DMF, DMA and DMSO.
[0023] Furthermore, the sulfonic acid is one or more selected from p-toluenesulfonic acid, benzenesulfinic acid, trifluoromethanesulfonic acid, (-)-10-camphorsulfonic acid, (+)-10-camphorsulfonic acid and methanesulfonic acid; preferably, the p-toluenesulfonic acid is p-toluenesulfonic acid monohydrate.
[0024] Preferably, L is any linking group containing an acyl, having the structure shown in formula (I):
(I) W R-wherein:

t.1KN
RI is selected from 0 0 N
--A
H r 0 , 0 0 , 0 =
, 9-µ- 0A-N
vr\I_ N-0 H I ,sN 110 2N ---\( =
R2 is selected from -1-0- , NI' , 0 , OA- OA-F
. F F

and salts thereof.
[0025] More preferably, L is selected from the following structures:
by0 0 ---A, 0 (N) 0 N-----j=L, I OH N .)t.OH rNvN.I.(vSji3OH
---.\( 0 , 0 , 0 0 , H
rOH ----.1.1 N-(-0)-)LOH
w 8 , , , n N--N___, --A
I N\INJ)¨
----\( N -----\ N

, , -A 0 r%\l'i4-_ N ,N
0 \I _________________________________________________________ I N)-L
0N' N
0' N

, , N N
,N r Nr.-) ,)0.L, N 0 \' N
0' --CNJ, - 8 0 .
[0026] More preferably, L'-MMAF is selected from the following structures:
O "=../\
0 0 flAr.NH
N,--,j-(isrt=IHJ=LN-r 0 0 O , O 1".../s, I :X1rNHJ(Nrr 0\ 0 ----\C I ; >I 0 0 HO 0 , 0 0 N NF /CirClyilr,NH
Rl.)L iOt.N

/
, ----- 0 0 44ric¨iNH
-41 N-(,0-)rs)crNI-1,..AN 0 0 w 8 1 0 1 E /0 0 \ HO 0 O , 0 0 CNYir NH

I E 1 0 0 \ HO 0 0 .,-7. /
, I
=,r0 N====.--",.
r 1 0 0 cMrNH
,Thr.NN.Ii,S)1,,,XNHly.).( 0\ 0 Ho 0 O 0 I 0 = 1 /0 0 =
[0027] Furthermore, the molar ratio of the acid to the corresponding monomethyl auristatin derivative is preferably greater than or equal to 1, or greater than or equal to 2.

[0028] Furthermore, the solution 1 is added into solution 2 evenly, preferably, by dropwise addition.
[0029] The present invention also provides use of the method according to any one of the foregoing in the production of an antibody-drug conjugate.
5 [0030] The method for producing an antibody-drug conjugate intermediate (specifically, a linking group-MMAF covalent conjugate) by addition of acid provided in the present invention is a method of adding an acid additive to convert MMAF into a salt to participate in the reaction, based on the traditional preparation method (the preparation method disclosed in line [0009] on page 2 of the description of Chinese 10 Patent Publication No. CN109824759A). After a series of reactions, we surprisingly find that the addition of the acid can significantly improve the yield of the final product. In addition, the low price of the acid (negligible relative to MMAF) can greatly reduce the production cost of the final ADC product. In addition, compared with the two-step process disclosed in Patent Publication No. CN109824759A, the method provided by the present invention adopts a one-step preparation process, in addition to a higher yield of the final product, which not only reduces the cost of the consumables, labor, equipment, site, raw materials and the like in the production, but also greatly reduces the production of the waste liquid, and thus reduces production costs and improves production efficiency, and is suitable for industrial large-scale production.
Brief description of the drawings [0031] Fig. 1 is a liquid chromatogram of the products obtained by adding various sulfonic acid additives in Example 2 of the present invention.
[0032] Fig. 2 is a line chart of the area ratio (area ratio refers to the ratio of the peak area of the product in the chromatogram to the reference area, wherein reference area is the peak area when the molar ratio of the acid additive to MMAF is equal to 1:1) of the reaction products obtained by adding different molar amounts of p-toluenesulfonic acid monohydrate in Example 3 of the present invention.
[0033] Fig. 3 is a liquid chromatogram of the products obtained by adding different molar amounts of N,N-diisopropylethylamine in Example 4 of the present invention.
Detailed description of the invention
11 / 39 Abbreviation [0034] Unless otherwise stated, all abbreviations used in the present invention have the same meaning as understood by those of ordinary skill in the art. As used in the present invention, the common abbreviations and their definitions are as follows:
Abbreviation Definition DCC N,N'-dicyclohexylcarbodiinaide EDCI 1-(3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride DIC N,N'-Diisopropylcarbodiimide HATU 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate HBTU 0-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate HBPIPU (Benzotriazol-1-yloxy)dipiperidinocarbenium hexafluorophosphate HBPyU 0-(benzotriazol-1-y1)-N,N,N,N'-dipyrrolidinocarbenium hexafluorophosphate HCTU 6-chlorobenzotriazol-1,1,3,3-tetramethyluronium hexafluorophosphate HDMA 14(dimethylamino)(morpholino)methylene]-1H-[1,2,3]triazolo14,5-bl pyridine-1 -ium 3-oxide hexafluorophosphate TATU 0-(7-azabenzotriazole-y1)-N,N,N',N'-tetramethyluronium tetrafluoroborate TBTU 0-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate TCTU 0-(6-chloro-1H-benzotriazol-1-y1)-N,N,N',N'-tetramethyluronium tetrafluoroborate TCFH N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate TDBTU N,N,N',N'-tetramethy1-0-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yOuronium tetrafluoroborate TFFH fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate BTFFH N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate TSTU 2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate PyBOP 1H-benzotriazol-1-yloxytripyrrolidinophosphonium Hexafluorophosphate PyCIOP Chlorotri(1-pyrrolidinyl)phosphonium hexafluorophosphate
12 / 39 PyAOP (3-hydroxy-3H-1,2,3-tri azolo [4,54A pyridinato-0)tri-1-pyrrolidinylphosphonium hexafluorophosphate PyCIU 1-(chloro-1-pyrrolidinylmethylene)pyrrolidinium hexafluorophosphate DEPBT 3-(diethoxyphosphoryloxy)-1,2,3-benzotrizin-4(3H)-one EEDQ 2-ethoxy-1-ethoxycarbony1-1,2-dihydroquinoline Mc Maleimidohexanoyl MMAF Monomethylauristatin F
DMF Dimethylformamide DMA Dimethylacetamide NMP NMP
DMSO Dimethyl sulfoxide Definition [0035] Various terms related to various aspects of the specification are used throughout the specification and claims. Unless otherwise indicated, such terms are given their ordinary meaning in the art. Other specifically defined terms should be understood in a manner consistent with the definitions provided herein.
[0036] As used herein, the terms "a" and "an" and "the" are used in accordance with standard practice and mean one or more, unless the context indicates otherwise. Thus, for example, reference to "an antibody-drug conjugate" includes a combination of two or more antibody-drug conjugates and the like.
[0037] It should be understood that wherever an aspect is described herein with the word "comprising", it also provides similar aspects described with "consisting of' and/or "substantially consisting of'.
[0038] Although the numerical ranges and parameter approximations shown in the broad scope of the present invention, the numerical values shown in the specific examples are described as accurately as possible. However, any numerical value inherently must contain a certain amount of error, which is caused by the standard deviation present in their respective measurements. In addition, all ranges disclosed herein are understood to cover any and all sub-ranges contained therein. For example,
13 a recorded range of "1 to 10" should be considered to include any and all sub-ranges between a minimum of 1 and a maximum of 10 (inclusive); that is, all sub-ranges beginning with a minimum of 1 or greater, such as 1 to 6.1, and sub-ranges ending with a maximum of 10 or less, such as 5.5 to 10.
[0039] As used in the present invention, "--" means that the group containing "--"
is connected to other groups through the chemical bond here.
[0040] The term "linking group" used in the present invention refers to a bifunctional or multifunctional molecule, which can react with a protein/antibody molecule and MMAF, respectively, and thus function as a "bridge" to link the protein/antibody to MMAF. The linking group used in the present invention specifically refers to a group containing an acyl in the structure.
[0041] The term "antibody-drug conjugate intermediate" in the present invention refers to a covalent conjugate of a linking group and MMAF.
Example [0042] The following further describes the present invention in combination with specific examples. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. The experimental methods without specific conditions in the following examples are generally performed under conventional conditions or conditions recommended by the manufacturer. The reagents without specific sources are conventional reagents purchased on the market. Unless otherwise stated, all percentages, ratios, proportions, or parts are by weight.
[0043] The units in weight-volume percentage in the present invention are well known to those skilled in the art, and for example, refer to the weight of a solute in 100 ml of a solution.
[0044] Unless otherwise defined, all specialties and sciences used herein are used in the same sense as that familiar to those skilled in the art. In addition, any method or material similar or equal to the content described can be used in the method of the present invention. The preferred embodiments and materials described herein are for illustration purposes only.
Date Recue/Date Received 2021-01-27
14 / 39 Example Mc-MMAF Preparation Method 1 (without adding acid) r.rcyty NH
lirrNr ===
N 0, 0 1101 Mc-OH MMAF

HATU, DMF, Oyt,iNH
DIPEA N

\ HO 0 0 = 0 /7, Mc-MMAF
[0045] 84.6 mg of Mc-OH and 144.6 mg of HATU were weighed and added into a 50 mL round bottom flask, then 5 mL of N,N-dimethylformamide was added into the round bottom flask using a 5 mL syringe, and then 165.4 'IL of N,N-diisopropylethylamine was added into the flask using a 200 [IL pipettor.
The flask was placed on a magnetic stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 146.4 mg of MMAF was weighed and added into a 25 mL round bottom flask, and then 10 mL of N,N-dimethylformamide was added into the flask using a 10 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was added into the MMAF solution using a 5 mL
plastic dropper. The ice bath was removed from the magnetic stirrer, and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 1.11, of sample was taken and added into a 1.5 mL centrifuge tube using a 10 1.IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken by a 1 ml syringe and passed through an organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0046] After the reaction was completed, the solvent was spin-dried with a rotary evaporator, and 5 mL of acetonitrile was added. The sample was taken using a 5 mL
syringe and filtered into a 10 mL sample bottle through organic phase needle filter, and then purified by preparative liquid chromatography. The preparative liquid chromatography was: mobile phase A: 1120, 0.1% HCOOH, mobile phase B: MeCN, 0.1% HCOOH, flow rate 40 mL/min, gradient: 25% B-70% B, 30 minutes, and a peak appeared at 25.1 minutes. The first injection was 5 mL, resulting 45 mL of the preparation solution. 5 mL of acetonitrile was added to the sample bottle again. The
15 /39 second injection was 5 mL, resulting 45 mL of the preparation solution. The obtained preparation solutions were combined into a 250 mL round-bottomed flask, and cooled in a refrigerator at -80 C for 3 h, and then freeze-dried in a lyophilizer to obtain 102.7 mg of pure Mc-MMAF product. Yield: 52%. LC-MS: (M + H) +: 924.4;
(M-H)-: 922.9.
Mc-MMAF Preparation Method 2 (adding trifluoroacetic acid) jyNH

\ HO 0 Mc-OH MMAF

HATU, DMF, 0 0 rrlfcM(NH
TFA, DIPEA
I 0 0 \ HO 0 Mc-MMAF
[0047] 84.8 mg of Mc-OH and 144.7 mg of HATU were weighed and added into a 50 mL round bottom flask, then 5 mL of N,N-dimethylformamide was added into the round bottom flask using a 5 mL syringe, and then 165.4 1.11_, of N,N-diisopropylethylamine was added into the flask using a 200 [IL pipettor.
The flask was placed on a magnetic stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 146.4 mg of MMAF and 22.8 mg of trifluoroacetic acid were weighed and added into a 25 mL round bottom flask, and then 10 mL of N,N-dimethylformamide was added into the flask using a 10 mL
syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The ice bath was removed from the magnetic stirrer, and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 [IL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 [tL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0048] After the reaction was completed, the solvent was spin-dried with a rotary
16/39 evaporator, and 5 mL of acetonitrile was added. The sample was taken using a 5 mL
syringe and filtered into a 10 mL sample bottle through organic phase needle filter, and then purified by preparative liquid chromatography. The preparative liquid chromatography was: mobile phase A: H20, 0.1% HCOOH, mobile phase B: MeCN, 0.1% HCOOH, flow rate 40 mL/min, gradient: 25% B-70% B, 30 minutes, and a peak appeared at 25.1 minutes. The first injection was 5 mL, resulting 45 mL of the preparation solution. 5 mL of acetonitrile was added to the sample bottle again, and the second injection was 5 mL, resulting 45 mL of the preparation solution.
The obtained preparation solutions were combined into a 250 mL round-bottomed flask, and cooled in a refrigerator at -80 C for 3 h, and then freeze-dried in a lyophilizer to obtain 114.1 mg of pure Mc-MMAF product. Yield: 62%. LC-MS: (M + H) +: 924.4;
(M-H)-: 922.9.
Mc-MMAF Preparation Method 3 (adding p-toluenesulfonic acid monohydrate) 0 0 1õ115,. NH
NOH N
HN H

\ HO 0 0 Mc-OH 0 /
MMAF

HATU,DIPEA,DMF,Ts0H 0 0 ri4-1.,,X NH
NH .J.L N
N0,0 Mc-MMAF
[0049] 84.6 mg of Mc-OH and 144.2 mg of HATU were weighed and added into a 50 mL round bottom flask, then 5 mL of N,N-dimethylformamide was added into the round bottom flask using a 5 mL syringe, and then 165.4 tiL of N,N-diisopropylethylamine was added into the flask using a 200 ILL pipettor.
The flask was placed on a magnetic stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 146.4 mg of MMAF and 34.8 mg of p-toluenesulfonic acid monohydrate were weighed and added into a 25 mL round bottom flask, and then 10 mL of N,N-dimethylformamide was added into the flask using a 10 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper.
The ice bath was removed from the magnetic stirrer, and the mixture was stirred for
17 /39 another 1 h. Then, the reaction was stopped, 10 t.LL of sample was taken and added into a 1.5 mL centrifuge tube using a 10 1.1L pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS
to check the reaction.
[0050] After the reaction was completed, the solvent was spin-dried with a rotary evaporator, and 5 mL of acetonitrile was added. The sample was taken using a 5 mL
syringe and filtered into a 10 mL sample bottle through organic phase needle filter, and then purified by preparative liquid chromatography. The preparative liquid chromatography was: mobile phase A: H20, 0.1% HCOOH, mobile phase B: MeCN, 0.1% HCOOH, flow rate 40 mL/min, gradient: 25% B-70% B, 30 minutes, and a peak appeared at 25.1 minutes. The first injection was 5 mL, resulting 45 mL of the preparation solution. 5 mL of acetonitrile was added to the sample bottle again, and the second injection was 5 mL, resulting 45 mL of the preparation solution.
The obtained preparation solutions were combined into a 250 mL round-bottomed flask, and cooled in a refrigerator at -80 C for 3 h, and then freeze-dried in a lyophilizer to obtain 125.9 mg of pure Mc-MMAF product. Yield: 68%. LC-MS: (M + H) +: 924.4;
(M-H)-: 922.9.
Mc-MMAF Preparation Method 4 (adding (-)-10-camphorsulfonic acid) Q, NH
HNXi.NH ,$)L

I E I /0 0 \ HO 0 0 Mc-OH 0 MMAF

HATU,DIPEA,DMF 0 0 NH
I Xõir, NH N
(-)-10-CPSA
I 0 I /0 0 s HO 0 Mc-MMAF
[0051] 84.2 mg of Mc-OH and 144.4 mg of HATU were weighed and added into a 50 mL round bottom flask, then 5 mL of N,N-dimethylformamide was added into the round bottom flask using a 5 mL syringe, and then 165.4 pL of N,N-diisopropylethylamine was added into the flask using a 200 1.1.1.
pipettor. The flask was placed on a magnetic stirrer, and after adding a stir bar, stirred at room temperature for 0.5 h. 147.0 mg of MMAF and 46.8 mg of (-)-10-camphorsulfonic acid were weighed and added into a 25 mL round bottom flask, and then 10 mL of
18/39 N,N-dimethylformamide was added into the flask using a 10 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirred in an ice bath. Under the ice bath cOndition, the Mc-OH system was transferred into the MMAF
solution using a 5 mL plastic droppe. The ice bath was removed from the magnetic stirrer, and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 L of sample was taken and added into a 1.5 mL centrifuge tube using a 10 L pipettor, and then 1 mL
of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0052] After the reaction was completed, the solvent was spin-dried with a rotary evaporator, and 5 mL of acetonitrile was added. The sample was taken using a 5 mL
syringe and filtered into a 10 mL sample bottle through organic phase needle filter, and then purified by preparative liquid chromatography. The preparative liquid chromatography was: mobile phase A: 1120, 0.1% HCOOH, mobile phase B: MeCN, 0.1% HCOOH, flow rate 40 mL/min, gradient: 25% B-70% B, 30 minutes, and a peak appeared at 25.1 minutes. The first injection was 5 mL, resulting 45 mL of the preparation solution. 5 mL of acetonitrile was added to the sample bottle, and the second injection was 5 mL, resulting 45 mL of the preparation solution. The obtained preparation solutions were combined into a 250 mL round-bottomed flask, and cooled in a refrigerator at -80 C for 3 h, and then freeze-dried in a lyophilizer to obtain 117.4 mg of pure Mc-MMAF product. Yield: 64%. LC-MS: (M + H) +: 924.4; (M-H)-:

922.9.
Mc-MMAF Preparation Method 5 (adding trifluoromethanesulfonic acid) o NH
OH HX,Tr. NH

I I 0 0 \ HO 0 0 Mc-OH 0 /
MMAF

HATU,DIPEA,DMF 0 0 cylr, NH
I N NH jt, \ HO 0 Mc-MMAF
[0053] 84.6 mg of Mc-OH and 144.7 mg of HATU were weighed and added into a 50 mL round bottom flask, then 5 mL of N,N-dimethylformamide was added into the round bottom flask using a 5 mL syringe, and then 165.4 L of
19 / 39 N,N-diisopropylethylamine was added into the flask using a 200 pL pipettor.
The flask was placed on a magnetic stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 146.5 mg of MMAF and 30.0 mg of trifluoromethanesulfonic acid were weighed and added into a 25 mL round bottom flask, and then 10 mL of N,N-dimethylformamide was added into the flask using a 10 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH

system was transferred into the MMAF solution using a 5 mL plastic droppe. The ice bath was removed from the magnetic stirrer, and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 I.LL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 [IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0054] After the reaction was completed, the solvent was spin-dried with a rotary evaporator, and 5 mL of acetonitrile was added. The sample was taken using a 5 mL
syringe and filtered into a 10 mL sample bottle through organic phase needle filter, and then purified by preparative liquid chromatography. The preparative liquid chromatography was: mobile phase A: H20, 0.1% HCOOH, mobile phase B: MeCN, 0.1% HCOOH, flow rate 40 mL/min, gradient: 25% B-70% B, 30 minutes, and a peak appeared at 25.1 minutes. The first injection was 5 mL, resulting 45 mL of the preparation solution. 5 mL of acetonitrile was added to the sample bottle, and the second injection was 5 mL, resulting 45 mL of the preparation solution. The obtained preparation solutions were combined into a 250 mL round-bottomed flask, and cooled in a refrigerator at -80 C for 3 h, and then freeze-dried in a lyophilizer to obtain 121.2 mg of pure Mc-MMAF product. Yield: 66%. LC-MS: (M + H) +: 924.4;
(M-H)-: 922.9.
[0055] In the preliminary test, we made further exploration on the basis of Mc-MMAF preparation method 1 mentioned above. When preparing the MMAF
reaction solution, the MMAF was first converted to salts by adding an acid or base reagent and then participated in the reaction. We performed the preliminary test by adding trifluoroacetic acid, potassium tert-butoxide and the like, and found that when formulating MMAF reaction solution by adding potassium tert-butoxide (Mc-MMAF
preparation method 2), the yield of Mc-MMAF product was significantly increased.
[0056] We then explored the effect of adding other acids, and found that the addition
20/39 of various acids has a surprising effect on yield. For example, compared with the control, when adding p-toluenesulfonic acid monohydrate (Mc-MMAF preparation method 3), the yield of Mc-MMAF has also been surprisingly improved, from 52%
to 68%, that is, the absolute value of the yield has been increased by 16%, and the relative value of the yield has been increased by 30.7% ((68%-52%)/52%) compared with the preparation method 1 without adding acid. In addition, the yields of Mc-MMAF product in the experimental group of adding (-)-10- camphorsulfonic acid and trifluoromethanesulfonic acid also reach 64% and 66%, respectively.
[0057] The test results show that by adding an acid reagent to the reaction system, the yield of Mc-MMAF can be effectively improved.
Example 2 Test results of adding various sulfonic acids 0 arr,.(rs,r NH
N7',.,./\,A0H NH

I E I /0 0 \ HO 0 0 Mc-OH 0 MMAF
1)HATU,DIPEA,DMF,(+10-CPSA
2)HATU,DIPEA,DMF,(+)-10-CPSA rr.,119,..rty NH
3)HATU,DIPEA,DMF,1)-CPSA I N NH L N 0 0 4)HATU,DIPEA,DMF,MeS03H I 0 I /0 0 , 's HO 0 SHIATU,DIPEA,DMF,CF3S0314 6)HATU,DIPEA,DMF,Ts0H Mc-MMAF
Test 1) adding (-)-10- camphorsulfonic acid [0058] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 22.3 1..11_, of N,N-diisopropylethylamine was added into the flask using a 100 tL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 6.3 mg of (-)-10- camphorsulfonic acid were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL
plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 gL of sample was taken and added into a 1.5 mL centrifuge tube using a 10 IAL pipettor, and then 1 mL of
21/39 acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 2) adding (+)-10- camphorsulfonic acid [0059] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 22.3 [d., of N,N-diisopropylethylamine was added into the flask using a 100 t.t.L pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 6.3 mg of (+)-10- camphorsulfonic acid were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL
plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 11.1_, of sample was taken and added into a 1.5 mL centrifuge tube using a 10 !IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 3) adding 10-camphorsulfonic acid [0060] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 22.3 1..t.L of N,N-diisopropylethylamine was added into the flask using a 100 1.11_, pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 6.3 mg of 10- camphorsulfonic acid were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper.
The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h.
Then, the reaction was stopped, 10 IlL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 1AL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe
22 / 39 and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 4) adding methanesulfonic acid [0061] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 22.3 iL of N,N-diisopropylethylamine was added into the flask using a 100 L pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 2.6 mg of methanesulfonic acid were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper.
The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h.
Then, the reaction was stopped, 10 L of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 1_, pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 5) adding trifluoromethanesulfonic acid [0062] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 n-IL flask, then I mL of N,N-dimethylformamide was added into the flask using a 1 mL pipettor, and then 22.3 L of N,N-diisopropylethylamine was added into the flask using a 100 1_, pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.1 mg of trifluoromethanesulfonic acid were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL
plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 I, of sample was taken and added into a 1.5 mL centrifuge tube using a 10 L pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then
23 / 39 loaded for LC-MS to check the reaction.
Test 6) adding p-toluenesulfonic acid monohydrate [0063] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 22.3 !IL of N,N-diisopropylethylamine was added into the flask using a 100 pL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.7 mg of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL
plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 p.L of sample was taken and added into a 1.5 mL centrifuge tube using a 10 pL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0064] The test results are shown in Fig. 1. The addition of various types of sulfonic acids, such as (-)-10-camphorsulfonic acid, (+)-10-camphorsulfonic acid, 10-camphorsulfonic acid, methanesulfonic acid, and trifluoromethanesulfonic acid in the reaction system can achieve a reaction promoting effect equivalent to the addition of p-toluenesulfonic acid monohydrate, and can effectively improve the yield of Mc-MMAF.
Example 3 Effect of different amounts of the acid additive Test 1) without acid additive [0065] 11.5 mg (0.055 mmol) of Mc-OH and 20.5 (0.054 mmol) mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a 1 mL pipettor, and then 35.7 pi- (0.216 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 tit. pipettor.
The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg (0.027 mmol) of MMAF was
24 / 39 weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 L, of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 L pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 2) the molar ratio of the acid to MMAF at 1:100 [0066] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 pL of N,N-diisopropylethylamine was added into the flask using a 100 !AL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 46 g (2.7*10-4 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.
After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 L of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 L pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 3) the molar ratio of the acid additive to MMAF at 1:20 [0067] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 L of N,N-diisopropylethylamine was added into the flask using a 100 L pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of
25 / 39 MMAF and 0.23 mg (13.5*104 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 1AL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 [IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a I ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 4) the molar ratio of the acid additive to MMAF at 1:10 [0068] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 1AL of N,N-diisopropylethylamine was added into the flask using a 100 1AL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 0.46 mg (2.7*10-3 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 L of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 pL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a I ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 5) the molar ratio of the acid additive to MMAF at 1:5 [0069] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 1.tL of N,N-diisopropylethylamine was added into the flask using a 100 1AL pipettor. The flask was placed on a parallel reactor stirrer, and after
26/39 adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 0.92 mg (5.4* i 3 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.
After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 [IL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 [IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 6) the molar ratio of the acid additive to MMAF at 2:5 [0070] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 1.tL of N,N-diisopropylethylamine was added into the flask using a 100 1AL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 1.84 mg (0.011 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 1AL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 [IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
= Test 7) the molar ratio of the acid additive to MMAF at 1:2 [0071] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 tL of N,N-diisopropylethylamine was added into the flask
27 / 39 using a 100 [IL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 2.3 mg (0.014 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.
After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 1AL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 1AL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 8) the molar ratio of the acid additive to MMAF at 1:1 [0072] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 1AL of N,N-diisopropylethylamine was added into the flask using a 100 1AL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.6 mg (0.027 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 [IL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 L pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 9) the molar ratio of the acid additive to MMAF at 2:1 [0073] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a
28 / 39 mL pipettor, and then 35.7 L of N,N-diisopropylethylamine was added into the flask using a 100 L pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 9.3 mg (0.054 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 L of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 L pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 10) the molar ratio of the acid additive to MMAF at 3:1 [0074] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 L of N,N-diisopropylethylamine was added into the flask using a 100 L pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 13.9 mg (0.081 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.
After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 [IL of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 [IL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 11) the molar ratio of the acid additive to MMAF at 4:1 [0075] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5
29/39 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 35.7 1.1L of N,N-diisopropylethylamine was added into the flask using a 100 1iL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 18.6 mg (0.108 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe.

After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 of sample was taken and added into a 1.5 mL
centrifuge tube using a 10 1_, pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0076] The test results are shown in Fig. 2. When the molar ratio of the acid to MMAF is greater than 1, the reaction is significantly promoted.
Example 4 Effect of different amounts of the organic base in solution 1 [0077] In order to verify whether the amount of the organic base used in the solution 1 (a solution containing a linking group) affects the result of the reaction, DIPEA was used in the example to further carry out related experiments.
Test 1) molar ratio of the basic additive (DIPEA) to the acid additive at 2:1 [0078] 11.5 mg (0.055 mmol) of Mc-OH and 20.5 mg (0.054 mmol) mg of HATU
were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a 1 mL pipettor, and then 8.9 1.IL (0.055 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 1.1L pipettor.
The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg (0.027 mmol) of MMAF and 4.6 mg (0.027 mmol) of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath
30/39 condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL
plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 p.L of sample was taken and added into a 1.5 mL centrifuge tube using a 10 1AL pipettor, and then 1 mL of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 2) molar ratio of the basic additive (DIPEA) to the acid additive at 3:1 [0079] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 13.4 1AL (0.081 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 1AL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.6 mg of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 1.1. of sample was taken and added into a 1.5 mL centrifuge tube using a 10 [IL pipettor, and then 1 mL
of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 3) molar ratio of the basic additive (DIPEA) to the acid additive at 4:1 [0080] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 17.9 1iL (0.108 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 [IL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.6 mg of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5
31 / 39 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 pL of sample was taken and added into a 1.5 mL centrifuge tube using a 10 !IL pipettor, and then 1 mL
of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 4) molar ratio of the basic additive (DIPEA) to the acid additive at 5:1 [0081] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 22.3 tiL (0.135 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 1i1_, pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.6 mg of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 trL of sample was taken and added into a 1.5 mL centrifuge tube using a 10 1.1L pipettor, and then 1 mL
of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 5) molar ratio of the basic additive (DIPEA) to the acid additive at 6:1 [0082] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 26.8 111, (0.162 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 1i1.. pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.6 mg of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Mc-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the
32 / 39 mixture was stirred for 1 h. Then, the reaction was stopped, 10 1AL of sample was taken and added into a 1.5 mL centrifuge tube using a 10 1AL pipettor, and then 1 mL
of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
Test 6) molar ratio of the basic additive (DIPEA) to the acid additive at 7:1 [0083] 11.5 mg of Mc-OH and 20.5 mg of HATU were weighed and added into a 5 mL flask, then 1 mL of N,N-dimethylformamide was added into the flask using a mL pipettor, and then 31.3 1.t.L (0.189 mmol) of N,N-diisopropylethylamine was added into the flask using a 100 !IL pipettor. The flask was placed on a parallel reactor stirrer, and after adding a stir bar, stirring was performed at room temperature for 0.5 h. 20.0 mg of MMAF and 4.6 mg of p-toluenesulfonic acid monohydrate were weighed and added into another 5 mL flask, and then 1 mL of N,N-dimethylformamide was added into the flask two times using a 1 mL syringe. After adding a stir bar, the flask was placed on a magnetic stirrer and stirring was performed in an ice bath. Under the ice bath condition, the Me-OH system was transferred into the MMAF solution using a 5 mL plastic dropper. The reaction flask was placed on the parallel stirrer and the mixture was stirred for 1 h. Then, the reaction was stopped, 10 1.11, of sample was taken and added into a 1.5 mL centrifuge tube using a 10 I.LL pipettor, and then 1 mL
of acetonitrile was added into the centrifuge tube using a 1 mL pipettor. The sample was taken using a 1 ml syringe and passed through organic phase needle filter, and then loaded for LC-MS to check the reaction.
[0084] In the entire reaction system, when the addition amount of MMAF is 0.027 mmol, the addition amount of Mc-OH is 0.055 mmol, the acid reagent is 0.027 mmol, and the total free carboxyl group present in the reaction system is 0.109 mmol.
According to the test result shown in FIG 3, when the molar amount of DIPEA
added is less than or equal to 0.108 mmol, there is no reaction or the reaction rate is low; and when the molar amount of DIPEA is greater than 0.108 mmol, that is, the molar amount of organic base in the system is greater than that of the free carboxyl groups in the reaction system, the reaction is promoted remarkably.
[0085] It is easy to see from the above examples that compared to the case where no acid was added (the preparation method 1 in Example 1), the method provided by the present invention (ie, the preparation of antibody-drug conjugate intermediate by addition of acid) significantly improves the yield of Mc-MMAF, which is an unexpected technical effect.
33/39 [0086] Therefore, according to the above-mentioned principle verified by the synthesis of Mc-MMAF as a test example, it can be inferred that converting the monomethyl auristatin derivative into a salt by adding an acid reagent to participate in the reaction can significantly promote the reaction and greatly improve the yield. In addition, the method not only reduces the cost of the consumables, labor, equipment, site, raw materials and the like in the production, but also greatly reduces the production of the waste liquid, and thus reduces production costs and improves production efficiency, and is suitable for industrial large-scale production.
[0087] The invention has been exemplified by various specific embodiments.
However, those of ordinary skill in the art can understand that the present invention is not limited to the specific embodiments. Those of ordinary skill in the art can make various changes or modifications within the scope of the present invention, and various technical features mentioned in various places in this specification can be combined with each other without departing from the spirit and scope of the present invention. Such modifications and variations are all within the scope of the present invention.

Claims (17)

34
1. A method for producing an antibody-drug conjugate intermediate by addition of acid, wherein the reaction scheme of the method is:
it cowl, agenr 2. Organlc h 3 Solverir A
L _______________________________________ > L" -rnonarnathyl auristatin derivative Monornethyl auristatin derivative 4 Acid 5. Solvent B
wherein L is a linking group containing an acyl;
L' is the residue of the linking group covalently attached to the monomethyl auristatin derivative;
the acid is one or more selected from trifluoroacetic acid and sulfonic acid;
solvent A and solvent B are polar or non-polar solvents; and the method comprises the following steps:
1) dissolving the linking group L, the condensing agent, and the organic base in the solvent A to obtain solution 1;
2) dissolving the monomethyl auristatin derivative and the acid in the solvent B to obtain solution 2; and 3) adding the solution 1 into the solution 2 to obtain the L'-monomethyl auristatin derivative via the condensation reaction between L and the monomethyl auristatin derivative;
wherein the molar amount of the organic base used in step 1) is greater than the molar amount of all free carboxyl group in the reaction system of step 3).
2. The method according to claim 1, wherein the monomethyl auristatin derivative includes MMAF, MMAE, and MMAD.
3. The method according to claim 1 or 2, wherein the reaction scheme of the method is as follows:
16343850.1 Date Recue/Date Received 2021-01-27 1.
' `N 0 HO /
= , INIAF
Conclensirr,) :Agent 2 Organic b[1-:e NH
3. Solvent A
Y NH, / II ri) N ON. 0 õ
4. Acid 6 . o 5. Solvent E
L' \BUJ
or Ofi µ:( NH' ' 4 s 8 0 1!) L + HN y =- N 0 O
Io , ndensing agent OH

2, Orrr F 0 yN
r, Lel I I 40 4. Acid iO ,01.4 5. Solvent B
L'-111:11AL
or N
i L , ON

NMI WI
CDnderi,Ing agent 2õ Orcianic 0 1 1 m, =
3õ i,01,,)4:rit -111c rnljt, 5. Solvent B
1...mmAn
4. The method according to any one of claims 1 to 3, wherein the condensing agent is one or more selected from DCC, EDCI, DIC, HATU, HBTU, HBPIPU, HBPyU, HCTU, HDMA, TATU, TBTU, TCTU, TCFH, TDBTU, TFFH, BTFFH, PyBOP, PyClOP, PyA0P, PyCIU, DEPBT and EEDQ.
16343850.1 Date Recue/Date Received 2021-01-27
5. The method according to claim 4, wherein the condensing agent is HATU.
6. The method according to any one of claims 1 to 5, wherein the organic base is one or more selected from N,N-diisopropylethylamine, triethylamine, pyridine, dimethyl aminopyri dine, triethylenediamine, N-methylmorpholine, 1,8-diazabicy cl o [5 . 4 . 01-7 -undecene, N-methylimidazole, quinucli dine, and trimethylpyridine.
7. The method according to claim 6, wherein the organic base is selected from N,N-diisopropylethylamine and triethylamine.
8. The method according to any one of claims 1 to 7, wherein the solvent A and the solvent B are each independently selected from DMF, DMA, NMP, methylene chloride, carbon tetrachloride, DMSO, chloroform, tetrahydrofuran, 1,4-dioxane, hexamethylphosphoryl triamide, N,N-dimethylpropyleneurea, ethylene glycol dimethyl ether and a mixture thereof, wherein the solvent A and the solvent B
may be the same or different.
9. The method according to claim 8, wherein the solvent A and the solvent B
are each independently selected from DMF, DMA and DMSO.
10. The method according to any one of claims 1 to 9, wherein the sulfonic acid is one or more selected from p-toluenesulfonic acid, benzenesulfinic acid, trifluoromethanesulfonic acid, (-)-10-camphorsulfonic acid, (+)-10-camphorsulfonic acid and methanesulfonic acid.
11. The method according to claim 10, wherein the p-toluenesulfonic acid is p-toluenesulfonic acid monohydrate.
12. The method according to any one of claims 1 to 11, wherein L is a linking 16343850.1 Date Recue/Date Received 2021-01-27 group containing an acyl, as shown in formula (I):

(I) wherein, --A ----I, ---- ----\K
R1 is selected from 0 , 0 N
----H r N nrNiN \.-0 , 0 0 , 0 =
, ';1,,, 0-24-+ OH I ,,N ,:N 46 ----i R2 is selected from %----N N , 0 , 0-µ- 0 F
F
F

and salts thereof.
,
13. The method according to claim 12, wherein L is selected from:

---I( 0 N
r 0 1 N I OH N .t, OH niN NI.Sj-LOH
-----i ----,s( 0 , 0 0 0 , 0 ---I( 0 H
OH 1 N0)-OH
0 , , 0 0 , 16343850.1 Date Recue/Date Received 2021-01-27 n N _____________________________________________________ N

----A ----A (--, NN--___ N ., 1\1 _____ - \
0/ \NJ
,,, ----- "----- N---//
O , 0 , O , N , N
----A 0 N \
H 0 N R \
N 'LtC)/N \N __ // N

, , .ro N N
, N r ) 0 r n_ii\JN 0 N j \N / , and 0 0 .
14. The method according to claim 13, wherein L'-MMAF is selected from:

N NH

----\K 1 O 0 ' /
1 0 0 \ HO 0 , O 14.,./\
NH
N r\,.( NH Ni/./N
0 0 0 0 \ HO 0 O ,., /
, -=,/\

H N
n_r N i\r NH .)-( NIrThf - 1 0 0 \ HO 0 0 1 0 _,7,.. /
, ---k ? X, 0 N 1 N.v(:)N NH NH
j=L Ni-y-y -----i 1 1 0 0 \ HO 0 , 16343850.1 Date Recue/Date Received 2021-01-27 , and r 0 0 NH
15. The method according to any one of claims 1 to 14, wherein the molar ratio of the acid to the monomethyl auristatin derivative is greater than or equal to 1.
16. The method according to any one of claims 1 to 15, wherein the solution 1 is added into solution 2 by dropwise addition.
17. Use of the method according to any one of claims 1 to 16 for producing an antibody-drug conjugate.
16343850.1 Date Recue/Date Received 2021-01-27
CA3076714A 2019-09-29 2019-11-14 Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof Active CA3076714C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910934570 2019-09-29
CN201910934570.0 2019-09-29
PCT/CN2019/118446 WO2021056754A1 (en) 2019-09-29 2019-11-14 Method for preparing antibody-drug conjugate intermediate by means of acid method and application thereof

Publications (2)

Publication Number Publication Date
CA3076714A1 CA3076714A1 (en) 2020-08-04
CA3076714C true CA3076714C (en) 2021-06-15

Family

ID=71166490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3076714A Active CA3076714C (en) 2019-09-29 2019-11-14 Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof

Country Status (2)

Country Link
CN (1) CN111328333B (en)
CA (1) CA3076714C (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090114443A (en) * 2007-02-09 2009-11-03 제넨테크, 인크. Anti-RWF4 antibodies and uses thereof
MX363116B (en) * 2012-06-07 2019-03-11 Ambrx Inc Prostate-specific membrane antigen antibody drug conjugates.
MX2015012899A (en) * 2013-03-14 2016-06-02 Abbvie Inc Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors.
CN106188293A (en) * 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 Anti-C-met antibodies and anti-C-met antibodies-cytotoxic drug conjugate and medical usage thereof
CN107915770B (en) * 2016-10-11 2020-08-25 联宁（苏州）生物制药有限公司 Antibody drug conjugate intermediate and preparation method thereof
CN109912684A (en) * 2019-03-08 2019-06-21 联宁（苏州）生物制药有限公司 A kind of Preparation Method And Their Intermediate of the drug-linker MC-MMAF for antibody drug conjugates

Also Published As

Publication number Publication date
CA3076714A1 (en) 2020-08-04
CN111328333A (en) 2020-06-23
CN111328333B (en) 2023-10-03

Similar Documents

Publication Publication Date Title
AU2019268215B2 (en) Process for preparing intermediate of antibody drug conjugate
EP3250238B1 (en) Antibody drug conjugates
EP2994152B1 (en) Conjugates for protection from nephrotoxic active substances
Ohm et al. Diversity-oriented A3-macrocyclization for studying influences of ring-size and shape of cyclic peptides: CD36 receptor modulators
US11833219B2 (en) Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
Popadyuk et al. Modern approaches to modification of bile acids for the synthesis of compounds possessing valuable physicochemical and biological properties
CA3076714C (en) Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof
EP4201429A1 (en) Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor
CA3085001C (en) One-pot process for preparing intermediate of antibody-drug conjugate
WO2024188213A1 (en) Double site-directed antibody-functional molecular conjugate, and preparation method therefor and use thereof
CN116217655B (en) A method for preparing an intermediate of a linker-drug conjugate
CN111205350A (en) Macrocyclic Thioate Prodrugs as Histone Deacetylase Inhibitors
EP3230300B1 (en) Inhibitors for inhibition of tumor metastasis
CN113164613B (en) Method for optimizing dimeric peptide-phospholipid conjugates
RU2840789C2 (en) Antibody-drug conjugate intermediate comprising sn38, and method for preparation thereof
RU2809116C2 (en) Amantine conjugate with antibody
KR102162351B1 (en) Drug-conjugated compound and uses thereof
HK40042301A (en) Preparation process of antibody drug conjugate intermediate
TW202432559A (en) Preparation method and application of a class of linker drugs and antibody-drug conjugates thereof
KULIKOV et al. Studies on the carbodiimide‐mediated model couplings of Z‐Pro‐Leu‐OH with benzoaza‐15‐crown‐5
HK40031377A (en) Thioester prodrugs of macrocycles as inhibitors of histone deacetylases